Mirae Asset Global Investments Co. Ltd. Purchases Shares of 750 Exact Sciences Co. (NASDAQ:EXAS)

Mirae Asset Global Investments Co. Ltd. bought a new position in Exact Sciences Co. (NASDAQ:EXAS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 750 shares of the medical research company’s stock, valued at approximately $49,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Exact Sciences by 16.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock worth $6,160,000 after purchasing an additional 12,349 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Exact Sciences by 5.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock worth $14,361,000 after purchasing an additional 10,356 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of Exact Sciences by 239.8% in the second quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company’s stock worth $3,320,000 after purchasing an additional 55,459 shares during the last quarter. William Blair Investment Management LLC bought a new position in shares of Exact Sciences in the second quarter worth approximately $163,896,000. Finally, Grandfield & Dodd LLC grew its holdings in shares of Exact Sciences by 142.5% in the first quarter. Grandfield & Dodd LLC now owns 55,224 shares of the medical research company’s stock worth $3,814,000 after purchasing an additional 32,453 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Price Performance

EXAS opened at $71.51 on Wednesday. The stock has a 50-day moving average price of $67.04 and a 200-day moving average price of $56.59. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98. The firm has a market cap of $13.21 billion, a PE ratio of -74.46 and a beta of 1.27. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62.

Analyst Ratings Changes

EXAS has been the topic of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of Exact Sciences from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Benchmark cut their price target on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Piper Sandler lifted their price target on shares of Exact Sciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, September 12th. Sanford C. Bernstein lifted their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Stifel Nicolaus cut their price target on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $80.64.

Insider Transactions at Exact Sciences

In other news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now owns 12,758 shares of the company’s stock, valued at $893,060. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.36% of the stock is owned by insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.